#United States #ATR-12 #Branford #Netherton syndrome #Azitra Inc

Azitra, Inc. Refutes False Securities Offering Report

Azitra, Inc. (NYSE American: AZTR), a biopharmaceutical firm specializing in dermatological treatments in clinical stages, has recently confronted the emergence of misleading information regarding its financial activities. On November 7, 2025, the company disclosed that erroneous reports suggested it had conducted a $44 million registered direct offering of securities. The company's officials made it clear that this speculation is entirely unfounded.

The statement from Azitra emphasized the necessity for investors, stakeholders, and the general public to rely solely on verified information disseminated through the company's official communication channels. In response to the false report, Azitra is actively working to trace the origins of this misinformation, reinforcing its commitment to transparency and accuracy in communications.

About Azitra, Inc.

Azitra, Inc. is dedicated to the development of innovative therapies in precision dermatology. The company is advancing its lead program, ATR-12, which is specifically designed to address Netherton syndrome. This rare and severe skin condition is characterized by an abnormality in skin barrier function, causing extensive skin challenges that can prove fatal, particularly in infants.

The ATR-12 program is currently engaged in a Phase 1b clinical trial involving adult patients suffering from Netherton syndrome—a group that has few, if any, approved treatment options. Alongside ATR-12, Azitra is also making progress with its second program, ATR-04, a treatment aimed at alleviating skin rashes associated with EGFR inhibitors, medications commonly prescribed for cancer treatment. This program has already received Fast Track designation from the FDA, a status that will aid in the expedited development of the therapy, which potentially impacts around 150,000 individuals in the United States.

Moreover, Azitra is developing ATR-01, a preclinical initiative focusing on ichthyosis vulgaris, another skin condition characterized by dry and scaly skin. The company anticipates submitting an Investigational New Drug application for this program in 2026.

What sets Azitra apart is its proprietary platform that harnesses engineered proteins and topical biotherapeutic products. This platform is enriched by an expansive microbial library containing approximately 1,500 bacterial strains. The development processes are further enhanced by integrating artificial intelligence and machine learning technologies, which aid in synthesizing data and predicting potential therapeutic outcomes using these strains.

In light of the false report circulating about a securities offering, Azitra remains resolute in its mission to produce imaginative treatments that cater to complex dermatological needs, focusing on fostering improve quality of life for individuals grappling with these significant yet often overlooked skin disorders. As the situation unfolds, the company assures its stakeholders and the public that it will continue to uphold open lines of communication, providing relevant updates as they become available. For further information, interested parties can visit Azitra, Inc.'s official website at azitrainc.com.

Lastly, Azitra encourages all investors to stay vigilant and rely on credible sources when seeking information about the company and its operations. By bolstering adherence to transparency standards, Azitra aims to reinforce trust between the company and its stakeholders amidst a rapidly evolving landscape characterized by both innovation and misinformation.